In conclusion, the results of our study strongly suggest that the polymorphisms within the IL-17A and IL-17F genes affect the susceptibility to RA, disease progression and response to treatment with anti-TNF inhibitors. The gene discussed is TNF; the disease is rheumatoid arthritis.